Search

Your search keyword '"Cai, Hanqing"' showing total 41 results

Search Constraints

Start Over You searched for: Author "Cai, Hanqing" Remove constraint Author: "Cai, Hanqing"
41 results on '"Cai, Hanqing"'

Search Results

1. SpreadDetect: Detection of spreading change in a network over time

4. Estimation of high-dimensional change-points under a group sparsity structure

6. Emotion Aware Reinforcement Network for Visual Storytelling

7. Dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial

8. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis

9. Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)

13. The Differential Expression of Long Noncoding RNAs in Type 2 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults

17. Atomically Interfacial Engineering on Molybdenum Nitride Quantum Dots Decorated N‐doped Graphene for High‐Rate and Stable Alkaline Hydrogen Production

19. Dapagliflozin improves early diabetic nephropathy by downregulating PPP2R2A and CXCL12/S100A13 through ROS- dependent

20. Plasma Fluorescent Oxidation Products and Bone Mineral Density Among Male Veterans: A Cross-Sectional Study

22. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study

23. The SEED study of dorzagliatin in drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial

24. Additional file 1 of Association between lipid biomarkers and osteoporosis: a cross-sectional study

31. 17-OR: Efficacy and Safety of Chiglitazar, a Novel PPARα/γ/d Pan-Agonist, in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial (CMAP)

33. Efficacy and Safety of the Peroxisome Proliferator-Activated Receptor Pan-Agonist Chiglitazar in Patients with Type 2 Diabetes (CMAP): A 24 Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase 3 Superiority Trial

34. miR‐218 regulates diabetic nephropathy via targeting IKK‐β and modulating NK‐κB‐mediated inflammation.

35. Interleukin-10 Protects Schwann Cells against Advanced Glycation End Products-Induced Apoptosis via NF-κB Suppression.

41. TRIB3 [corrected] is implicated in glucotoxicity- and endoplasmic reticulum-stress-induced [corrected] beta-cell apoptosis.

Catalog

Books, media, physical & digital resources